Petra Glander - Academia.edu (original) (raw)

Uploads

Papers by Petra Glander

Research paper thumbnail of Renal transplantation - clinical studies - 2

Research paper thumbnail of Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy

Transplantation Proceedings, Aug 1, 2002

Research paper thumbnail of PUK6 The Economic Burden of Post-Transplant Events in Renal Transplant Patients in Germany (The Portrait Study)

Value in Health, Nov 1, 2012

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of an Initially Intensified Dosing Regimen Versus a Standard Dosing Regimen of Enteric-Coated Mycophenolate Sodium (Ec-MPS) in Renal Transplant Patients

Transplantation, Jul 27, 2008

Research paper thumbnail of Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients

Transplantation Proceedings, Nov 1, 2001

Research paper thumbnail of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis

The Journal of Clinical Pharmacology, Jul 1, 2007

ABSTRACT

Research paper thumbnail of Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients

Clinical Journal of The American Society of Nephrology, Mar 1, 2010

Research paper thumbnail of Die Verringerung der Cyclosporinexposition ist bei mit magensaftresistenter Mycophenol-säure und Basiliximab behandelten De-novo- Nierentransplantatempfängern sicher und wirksam

Nieren-und Hochdruckkrankheiten, Jun 1, 2007

Research paper thumbnail of MO105TELEMEDICAL Surveillance and Optimized Treatment of Blood Pressure in Kidney Transplant Recipients

Nephrology Dialysis Transplantation, May 1, 2021

Research paper thumbnail of Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients

Transplantation Proceedings, Dec 1, 2018

Research paper thumbnail of Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients

Transplantation, Apr 15, 2011

Research paper thumbnail of Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients

Transplantation Proceedings, Aug 1, 2002

Research paper thumbnail of Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes

Transplantation, Feb 1, 2007

ABSTRACT

Research paper thumbnail of MP725EXTENDED Release Tacrolimus in Kidney Allograft Recipients - Pharmacokinetic and Economical Aspects

Nephrology Dialysis Transplantation, May 1, 2016

Research paper thumbnail of An Intensified Dosing of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Results in Improved Efficacy Without Compromising Safety: 1 Year Follow-Up Results

Transplantation, Jul 1, 2010

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (Ec-MPS) in Maintenance Renal Transplant Patients with Tacrolimus as Basic Immunosuppression

Transplantation, Jul 1, 2004

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients

American Journal of Transplantation, Apr 1, 2007

The aim of this single‐center crossover substudy was to assess pharmacokinetics and pharmacodynam... more The aim of this single‐center crossover substudy was to assess pharmacokinetics and pharmacodynamics [inosine 5′‐monophosphate dehydrogenase (IMPDH) activity] of enteric‐coated mycophenolate sodium (EC‐MPS) and mycophenolate mofetil (MMF) at steady‐state conditions. Stable maintenance renal transplant patients on 1 g MMF b.i.d. participating in a double‐blind, multicenter study, were randomized to receive EC‐MPS (720 mg b.i.d.) or continue receiving MMF (1000 mg b.i.d.) for 12 months. Thereafter, all patients (n = 18) received 720 mg EC‐MPS b.i.d. Area under the plasma mycophenolic acid (MPA) concentration–time curve with EC‐MPS (57.4 ± 15.0 μg h/mL) fulfilled bioequivalence criteria (geometric mean 0.98 (90% CI: 0.87–1.11) compared to MMF (58.4 ± 14.1 μg h/mL). Consistent with the delayed release characteristics of EC‐MPS, peak MPA concentration (geometric mean 0.89; 90% CI: 0.70–1.13) occurred approximately 0.5 h later (p < 0.05) and predose MPA levels (geometric mean 2.10; 90% CI: 1.51–2.91) were higher and more variable, not fulfilling bioequivalence criteria. IMPDH activity inversely followed MPA concentrations and was inhibited to a similar degree (approximately 85%) by both formulations. The calculated value for 50% IMPDH inhibition was identical for both drugs. In conclusion, equimolar doses of EC‐MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC‐MPS exhibits more variable predose levels and Tmax. Overall, IMPDH activity reflected MPA pharmacokinetics.

Research paper thumbnail of SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY

Nephrology Dialysis Transplantation, 2018

Research paper thumbnail of No influence of the MDR-1 C3435T polymorphism on cyclosporine absorption profiles and tacrolimus dosage or renal function in stable renal transplant recipients

Research paper thumbnail of SP721Evaluation of Main Diagnoses of Kidney Transplant Recipients and DRG-Costs in German Health Care System

Nephrology Dialysis Transplantation, 2019

Research paper thumbnail of Renal transplantation - clinical studies - 2

Research paper thumbnail of Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy

Transplantation Proceedings, Aug 1, 2002

Research paper thumbnail of PUK6 The Economic Burden of Post-Transplant Events in Renal Transplant Patients in Germany (The Portrait Study)

Value in Health, Nov 1, 2012

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of an Initially Intensified Dosing Regimen Versus a Standard Dosing Regimen of Enteric-Coated Mycophenolate Sodium (Ec-MPS) in Renal Transplant Patients

Transplantation, Jul 27, 2008

Research paper thumbnail of Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients

Transplantation Proceedings, Nov 1, 2001

Research paper thumbnail of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis

The Journal of Clinical Pharmacology, Jul 1, 2007

ABSTRACT

Research paper thumbnail of Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients

Clinical Journal of The American Society of Nephrology, Mar 1, 2010

Research paper thumbnail of Die Verringerung der Cyclosporinexposition ist bei mit magensaftresistenter Mycophenol-säure und Basiliximab behandelten De-novo- Nierentransplantatempfängern sicher und wirksam

Nieren-und Hochdruckkrankheiten, Jun 1, 2007

Research paper thumbnail of MO105TELEMEDICAL Surveillance and Optimized Treatment of Blood Pressure in Kidney Transplant Recipients

Nephrology Dialysis Transplantation, May 1, 2021

Research paper thumbnail of Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients

Transplantation Proceedings, Dec 1, 2018

Research paper thumbnail of Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients

Transplantation, Apr 15, 2011

Research paper thumbnail of Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients

Transplantation Proceedings, Aug 1, 2002

Research paper thumbnail of Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes

Transplantation, Feb 1, 2007

ABSTRACT

Research paper thumbnail of MP725EXTENDED Release Tacrolimus in Kidney Allograft Recipients - Pharmacokinetic and Economical Aspects

Nephrology Dialysis Transplantation, May 1, 2016

Research paper thumbnail of An Intensified Dosing of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Results in Improved Efficacy Without Compromising Safety: 1 Year Follow-Up Results

Transplantation, Jul 1, 2010

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (Ec-MPS) in Maintenance Renal Transplant Patients with Tacrolimus as Basic Immunosuppression

Transplantation, Jul 1, 2004

Research paper thumbnail of Pharmacokinetic and Pharmacodynamic Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients

American Journal of Transplantation, Apr 1, 2007

The aim of this single‐center crossover substudy was to assess pharmacokinetics and pharmacodynam... more The aim of this single‐center crossover substudy was to assess pharmacokinetics and pharmacodynamics [inosine 5′‐monophosphate dehydrogenase (IMPDH) activity] of enteric‐coated mycophenolate sodium (EC‐MPS) and mycophenolate mofetil (MMF) at steady‐state conditions. Stable maintenance renal transplant patients on 1 g MMF b.i.d. participating in a double‐blind, multicenter study, were randomized to receive EC‐MPS (720 mg b.i.d.) or continue receiving MMF (1000 mg b.i.d.) for 12 months. Thereafter, all patients (n = 18) received 720 mg EC‐MPS b.i.d. Area under the plasma mycophenolic acid (MPA) concentration–time curve with EC‐MPS (57.4 ± 15.0 μg h/mL) fulfilled bioequivalence criteria (geometric mean 0.98 (90% CI: 0.87–1.11) compared to MMF (58.4 ± 14.1 μg h/mL). Consistent with the delayed release characteristics of EC‐MPS, peak MPA concentration (geometric mean 0.89; 90% CI: 0.70–1.13) occurred approximately 0.5 h later (p < 0.05) and predose MPA levels (geometric mean 2.10; 90% CI: 1.51–2.91) were higher and more variable, not fulfilling bioequivalence criteria. IMPDH activity inversely followed MPA concentrations and was inhibited to a similar degree (approximately 85%) by both formulations. The calculated value for 50% IMPDH inhibition was identical for both drugs. In conclusion, equimolar doses of EC‐MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC‐MPS exhibits more variable predose levels and Tmax. Overall, IMPDH activity reflected MPA pharmacokinetics.

Research paper thumbnail of SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY

Nephrology Dialysis Transplantation, 2018

Research paper thumbnail of No influence of the MDR-1 C3435T polymorphism on cyclosporine absorption profiles and tacrolimus dosage or renal function in stable renal transplant recipients

Research paper thumbnail of SP721Evaluation of Main Diagnoses of Kidney Transplant Recipients and DRG-Costs in German Health Care System

Nephrology Dialysis Transplantation, 2019

Log In